Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK3 | O43293 | 5/20 | 0.47 |
| ▸ | PIM1 | P11309 | 5/20 | 0.47 |
| ▸ | PRKACA | P17612 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.47 |
| ▸ | GSK3A | P49840 | 5/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | CDK8 | P49336 | 4/20 | 0.47 |
| ▸ | FLT1 | P17948 | 3/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 3/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23846517 | 0.82 | ICAM1 (0.53) | DAPK3PIM1PRKACAKDRMAPK8 | |
| SCHEMBL4463166 | 0.73 | ICAM1 (0.56) | DAPK3PIM1PRKACAKDRMAPK8 | |
| SCHEMBL7055757 | 0.72 | ICAM1 (0.63) | CDK8ICAM1SELEVCAM1CCNC | |
| SCHEMBL7057328 | 0.72 | ICAM1 (0.60) | PIM1PRKACAGSK3AGSK3BCDK5 | |
| SCHEMBL27688039 | 0.72 | NOS3 (0.38) | KDRLIMK1CDK5AURKBROCK1 | |
| SCHEMBL8140505 | 0.72 | NOS2 (0.41) | KDRAURKBROCK1AURKAMAP4K4 | |
| SCHEMBL6453012 | 0.71 | HCAR2 (0.37) | MAPK1PIM2 | |
| SCHEMBL6453018 | 0.71 | HCAR2 (0.37) | MAPK1PIM2 | |
| SCHEMBL9431027 | 0.69 | PLAU (0.73) | DAPK3PIM1PRKACAKDRMAPK8 | |
| SCHEMBL6436332 | 0.69 | CYP2A6 (0.49) | KDRAURKBROCK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | DAPK3 3516/4885PIM1 2304/4885PRKACA 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.